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and these costs are increasing compared to year to year. Policy interventions did not 
effected biotechnological medicine sales negatively. While big differences between 
the biotechnological and non-biotechnological medicine box sales will continue, 
the gap between the biotechnological and non-biotechnological medicines total 
amount will be closer.
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Objectives: There are concerns that the time taken to develop innovative new drugs 
is increasing, delaying access to and increasing the costs of new medicines. Both the 
clinical trial stage and regulatory approval stage for new drugs are important compo-
nents of overall development time, and we sought to determine whether the length 
of either of these stages is increasing, using new anti-viral drugs launched in the UK 
as a case-study. MethOds: New anti-viral drugs launched in the UK between 1981 
and 2013 were identified from the British National Formulary. Initiation of clinical 
development was determined from Pharmaprojects (Informa Healthcare) and Medline 
searches; the Investigational New Drug Application or first report of phase I trials 
was taken as the start of clinical development, whichever was earlier. Regulatory 
submission and approval dates were obtained from the European Medicines Agency 
and UK Medicines and Healthcare Regulatory Agency. Results: 43 new anti-viral 
drugs were launched in the UK between 1981 and 2013, with a mean time from start 
of clinical trials to approval of 6.4 years. This period increased from 4.8 years for drugs 
launched 1981-93, to 6.0 years for those launched 1994-2003, and 7.9 years for those 
launched 2004-2013; and a statistically significant positive linear trend was observed 
(r= 0.47). The mean time from regulatory submission to approval was 1.1 years, but 
no significant linear trend was seen for this time period (r= 0.20). New drugs for HIV 
typically spent less time in clinical development than other anti-viral drugs (mean 
5.7 vs 7.3 years, p= 0.049). However clinical development times for HIV and other anti-
viral drugs increased at a similar rate. cOnclusiOns: For anti-viral drugs launched 
in the UK, the time spent in clinical development has increased markedly since the 
1980s, and this increase is not related to increasing time taken for regulatory approval.
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Objectives: Turkish Ministry of Health (MoH) initiated Health Transformation 
Program (HTP) in 2002. HTP impacted all clinical and economic outcomes of health 
including pharmaceutical sales by improving access to health services. Total phar-
maceutical market reached US $ 8 billion in last 10 years. HTP improved health 
coverage and access to health services, additional policies are implemented by MoH 
for controlling this increasing trend on pharmaceutical consumption. The aim of 
this analysis is to understand the impact of selected 5 major policy changes to total 
pharmaceutical consumption in between 2002-2012. MethOds: 132 months sales 
data with segmented regression analysis for interrupted time series were used. 
International reference pricing of pharmaceuticals (RF), mandatory reimbursement 
dossier submission for new molecules, new indications and line extensions with 
medical and economic evaluations (MRDS), auditing for good manufacturing prac-
tice (GMP), family physician system (FP) and compulsory medical service for physi-
cians (CMS) were selected as five major policies that may affect cost, demand and 
supply of pharmaceuticals. We analyzed possible breaks in trends prior and after 
the implementation of 5 selected policies of the HTP. The analysis was conducted for 
cost (CS) and unit sales (US) for all pharmaceutical products. The Durbin-Watson d 
statistics of SPSS version 20.0 was used as a test for serial correlation of error terms. 
Shift in slope with p< 0.05 was considered as statistically significant. Results: All, 
except for RF policy changes, had a negative impact on the trends for CS. RF policy 
did not reverse the trends in CS and US however it slowed positive trend in CS signif-
icantly down. All policies hindering impact on the increasing trend in US. However, 
only RF and CMS policies reached statistically significant level. cOnclusiOns: 
Policies within the HTP framework were successful to control pharmaceutical 
expenditures while improving access to health care. International reference pric-
ing has a limited impact on controlling growth of pharmaceutical market.
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Objectives: To provide an overview of biosimilars uptake in Europe and assess 
policies and initiatives that might boost uptakes of biosimilars in European coun-
tries. MethOds: A literature review was conducted from European and national 
health authorities websites, Generics and Biosimilars Initiative (GaBi) website, 
Medline® database, and available grey literature. Results: To date, 17 biosimi-
lars were granted marketing authorization throughout the European Union and 
the European Medicines Agency released 9 product-specific biosimilar guidelines. 
Recent approval of the first monoclonal antibody biosimilar of infliximab dem-
onstrates the evolution of the European regulatory framework over time allowing 
approval of structurally complex molecules. Despite Europe has been a pioneer in 
this regulatory path, biosimilars uptake still remains limited (about 30% to 50% 
volume uptake) with modest price discounts from the originators (15% to 30%). If 
Germany authorized substitution of biological products produced by a same manu-
facturer in 2011, none of the Members States had allowed substitution of biological 
products from different manufacturers so far. With adoption of the 2014 social 
Objectives: To assess the global economic consequences for French hospitals of 
the European Commission (EC) decision to strengthen administration conditions 
of intravenous iron products (IIP) (iron sucrose (IS) and ferric carboxymaltose (FC)) 
due to safety concerns. Following this EC decision, in February 2014, French Health 
Authorities decided to give a hospital-restricted status (HRS) to IIP. MethOds: We 
compared, in acute care (medicine, -surgery-obstetrics) hospitals, IIP consumption 
and expenditure (extracted from SAP software) before (2012 vs. 2013) and before-after 
(02/2013-04/2013 vs. 02/2014-04/2014) they had a HRS, and the number of diagnosis-
related group “sessions of chemotherapy for non-tumor disease” (DRG-CNTD) linked 
to anemia (Technical Agency of Information on Hospitals data). Results: 20 hospitals 
were included. Before they had a HRS, IIP global consumption in volume increased by 
9.6% (i. e. € 171,022 spent more) in a year. After IIP had a HRS, the increase was 16.7% 
(i. e. € 164,338 spent more) in 3 months (02/2013-04/2013 vs. 02/2014-04/2014). 23.7% of 
the increase was attributable to day hospital admissions (DHA) and 4.4% to dialysis 
units. FC consumption was 23.9% higher (i. e. € 188,838 spent more) in 2014 compared 
to 2013, whereas IS consumption was 16.4% lower (i. e. € 24,500 spent less). DHA in 
DRG-CNTD linked to anemia increased by a factor of 1.8. cOnclusiOns: DHA as 
part of the DRG-CNTD is the only way to finance this additional hospital activity (no 
additional funding for traditional hospital care). FC’s cost of daily treatment (€ 120 
to € 150) is about 20 times IS’s (€ 5.2 to € 7.8), while a single tariff is allocated for the 
DRG-CNTD (drug case-mix: € 62, whatever the drug). Costs of the FC increasing use 
to manage anemia may be offset by administration of other drugs, or the DRG-tariff 
should be adjusted. Another alternative would be to implement a tender between IIP, 
taking into account the cost-effective ratio of each drug.
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Objectives: The increase in PBS expenditure over the past two decades led to 
the Australian Government implementing several cost containment measures. The 
objective of the present study was to investigate the impact of these reforms on PBS 
prescribing volumes and expenditure. MethOds: Data retrieved from Medicare 
Australia’s PBS Statistics database provided monthly government expenditure (ben-
efit) and prescription volume (service) data. Segmented linear regression models 
were used to analyse the time series data starting from 1 January 1992 to 31 March 
2012. In each segment, between implementing the cost containment measures, two 
parameters, the level and trend were used to estimate the impact of the interven-
tion. A lag of 12 months was applied to adjust for seasonality and forward stepwise 
eliminations were applied to obtain a parsimonious model. Seven cost containment 
measures were investigated: the economic evaluation requirement for drug listing 
(1/01/1993), re-supply limits (1/11/1994), two co-payment increases (1/01/1997 & 
1/01/2005), therapeutic group premium (TGP) policy (1/02/1998), safety net 20-day 
rule (1/01/2006), and price reductions in multiple brand drugs in Formulary 2 (F2) 
(1/08/2008). Results: All interventions except the re-supply limits policy were 
found to have a significant impact on PBS services or benefits. Reductions in the 
services and benefits trend were observed in two measures, the TGP policy and 
safety net 20-day rule while a reduction in the services trend was observed for 
the economic evaluation requirement measure. No significant trend changes were 
observed in the post F2 price reductions while higher co-payments resulted in a 
reduction in the level of services followed by an increase in the trend of services and 
benefits. cOnclusiOns: Many of the cost containment measures implemented 
in Australia have been effective in containing cost. Among these measures, the 
safety net 20-days rule was estimated to be the most effective in reducing drugs 
utilisation and expenditure.
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Objectives: In 2003 Health Transformation Program and in 2006 Social Security 
Reform were launched in Turkey. At the end of the years 2009 and 2011 price cuts 
were done by the Government and between the years 2010-2012, there was a global 
budget implementation in Turkey. The top 100 medicines, annual average highest 
amount of sales of between 2008-2013, had one to four of the total pharmaceutical 
market value in 2013. We aimed to examine the status of biotech-medicines in the 
first 100 medicine’s and evaluate the effects of policy interventions on these medi-
cine sales. MethOds: While pharmaceutical sales data were obtained from the IMS 
Health-Turkey data base, prices and characteristics of medicines were obtained from 
the Turkish Medicine and Medical Devices Agency data bases. Each group (biotech/
nonbiotech-medicines) was analyzed using TRAMO and SEATS method. Results: 
19 medicines are biotechnological. In 2009 compared to 2008 while biotech-med-
icines amount increased by 43.8%, nonbiotech-medicines amount increased by 
14.2%. In subsequent years, an increase over the previous year is observed at lower 
rates for biotech-medicines. This total amount has decreased compared to previous 
years for nonbiotech-medicines. 2014 and 2015 for the consumption of biotechno-
logical medicines was estimated to be around 9 million boxes, expenditure for 2014 
of 1360 million Turkish Liras (TL) and 2015 million TL for the year 2015. On the other 
hand, non-biotechnological medicines consumption would be approximately 185 
million boxes and for the year 2014 2225 million TL, for the year 2015 2280 million 
TL are projected. cOnclusiOns: Biotechnological medicines have high unit costs 
